FUNDAMENTALS · Fundamentals · AU Healthcare

EMVision Medical Devices (EMV) Fundamentals 2026 — Revenue Analysis | SniperIQ

EMVision Medical Devices (EMV) is a AU-listed Healthcare company in Medical - Devices with a market capitalization of A

52M, trading at A
.64 on the ASX. This SniperIQ fundamentals page covers EMVision Medical Devices's valuation, profitability (net margin -652.6%), revenue (A$5M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA
52M
Net Margin-652.6%
Revenue (FY25)A$5M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is EMVision Medical Devices's market cap?

EMVision Medical Devices (EMV) has a market capitalization of approximately A

52M, trading at A
.64 on the ASX. Market cap moves with the live share price.

What is EMVision Medical Devices's P/E ratio?

EMVision Medical Devices's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 7.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is EMVision Medical Devices?

EMVision Medical Devices runs a net profit margin of -652.6%, a gross margin of 86.3%, and an operating margin of -825.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does EMVision Medical Devices generate?

EMVision Medical Devices reported revenue of A$5M for fiscal year 2025, with net income of -A

0M and earnings per share (EPS) of -0.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does EMVision Medical Devices pay a dividend?

EMVision Medical Devices does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is EMVision Medical Devices financially healthy?

EMVision Medical Devices carries a debt-to-equity ratio of 0.20x and a current ratio of 12.94x, with a market beta of 1.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is EMVision Medical Devices a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For EMVision Medical Devices (EMV) the key facts are: market cap A

52M, revenue A$5M, 52-week range 1.47-2.43. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track EMVision Medical Devices's full fundamentals live

Get EMVision Medical Devices's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Actinogen Medical (ACW) fundamentals · Qatari German Company for Medical Devices (Q.P.S.C.) (QGMD.QA) fundamentals · ADC Therapeutics (ADCT) fundamentals · Dimerix (DXB) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons